ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Completion of Paired Serological Testing Algorithms for Spotted Fever Rickettsiosis and Ehrlichiosis, North Carolina: 2017-2020.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEhrlichia and Rickettsia are tickborne pathogens capable of causing severe disease. Paired serological testing, involving both acute and convalescent samples, remains the primary method of diagnostic confirmation and source of surveillance data. Yet, few patients complete recommended testing algorithms.
methodsWe examined the demographic, clinical, and geographic factors associated with obtainment of convalescent samples for patients with suspected ehrlichiosis and spotted fever rickettsiosis using results from a large academic center in North Carolina between 2017 and 2020.
resultsMore than 4400 patients underwent serological testing of an acute sample for Rickettsia (N = 4224) and Ehrlichia (N = 2339); however, only 15.0% (662/4415) had testing performed on a convalescent sample. Over the study period, the proportion of convalescent testing completed increased from 4% to 23% for Ehrlichia, 7% to 11% for Rickettsia, and 12% to 28% for both. A reactive test on the acute sample, undergoing testing for both pathogens, and proximity to a health facility were significantly associated with obtainment and testing of a convalescent sample. The presence of a reactive acute titer for Ehrlichia and Rickettsia had 8.3 (95% confidence interval, 6.3-10.9) and 8.2 (95% confidence interval, 6.5-10.3) times the probability of obtainment of a convalescent sample compared to nonreactive results, respectively.
conclusionsOur findings suggest that clinicians' knowledge of tickborne disease testing practices, in addition to patient distance to health facilities, contribute to poor performance of testing completion. Moreover, these results highlight the need for more investment in public health surveillance and, ultimately, assays that are not dependent on convalescent testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.